The award recognizes Saphire's leadership and innovative research toward addressing the urgent need for effective antibody therapeutics against COVID-19 and viral threats such as Ebola and Lassa virus.
LA JOLLA, CA—Scientists from La Jolla Institute for Immunology (LJI) and The University of Southampton, UK, have uncovered a group of immune cells that may drive severe asthma. These cells, called cytotoxic CD4+ tissue-resident memory T cells, gather in the lungs and appear to possess the molecular weaponry to cause the most harm in men who developed asthma later in life.
La Jolla Institute for Immunology (LJI) scientists have published a pair of studies that show how we might harness CD4+ T cells while boosting the cancer-fighting power of CD8+ "killer" T cells.
According to new research in the journal Immunity, T cells have a nuclear receptor doing something very odd—but very important—to help them fight pathogens and destroy cancer cells.
The study, led by scientists at La Jolla Institute for Immunology (LJI), reveals the inner workings of viral factories, clusters of viral proteins and genomes that form in host cells.
Support for early career researchers is about to get a major boost, thanks to a new fellowship fund established by leaders at La Jolla Institute for Immunology (LJI) and Japan-based global pharmaceutical corporation, Kyowa Kirin, Inc.
In a new study, scientists at La Jolla Institute for Immunology (LJI) compared the immune response of individuals who received older versus newer versions of the whooping cough vaccine. The unexpected findings may help explain the recent rise in whooping cough cases and point to potential targets for the next generation of vaccines.
Immune system researchers have designed a computational tool to boost pandemic preparedness. Scientists can use this new algorithm to compare data from vastly different experiments and better predict how individuals may respond to disease.
Scientists at La Jolla Institute for Immunology show that T cells can recognize several different viral targets, called "antigens," shared between most coronaviruses, including common cold coronaviruses and SARS-CoV-2. They also looked more in-depth at what fragments of these antigens, called “epitopes,” are recognized and how conserved they are across different coronaviruses.
La Jolla Institute for Immunology (LJI) is pleased to welcome biophysicist and immune system researcher Tal Einav, Ph.D., to the Institute’s faculty. His laboratory at LJI will develop new tools in computational biology and shed light on how human antibodies neutralize deadly viruses.
A San Diego team, led by scientists at La Jolla Institute for Immunology (LJI), has won the top prizes in the Nucleate Activator competition. Out of 1,000 initial competitors, the LJI team advanced to the final four teams and swept all the prizes they entered for. Their winning research proposal outlines how scientists could stop dengue virus and Zika virus by developing sophisticated vaccines that activate both B cells and T cells.
In a new study, published in Nature Cell Biology, scientists at La Jolla Institute for Immunology (LJI) explored the location, function, gene expression, and metabolism of MAIT cells in the mouse lung.
In a new investigation, scientists from La Jolla Institute for Immunology (LJI) have shown how antibodies, collected from a clinical study volunteer, bind to the SARS-CoV-2 Spike protein to neutralize the virus.
La Jolla Institute for Immunology (LJI) Instructor Estefania Quesada Masachs, M.D., Ph.D., has won the 2023 Young Investigator of the Year Award from the Network for Pancreatic Organ donors with Diabetes (nPOD). This prestigious award recognizes Quesada Masachs' groundbreaking research in type 1 diabetes.
There are no vaccines or therapies available for lymphocytic choriomeningitis virus (LCMV) infection. This pathogen spreads easily and is extremely common in people worldwide.
A new grant of over $17 million from the National Institute of Allergy and Infectious Diseases (NIAID) has established La Jolla Institute for Immunology (LJI) as the leading institute for human immunology data curation, analysis, and dissemination. With this funding, LJI has taken the helm of the Human Immunology Project Consortium Data Coordinating Center, a critical tool in the effort to fuel scientific collaboration in immunoprofiling and highlight findings from the overall Human Immunology Project Consortium (HIPC).
Inmazeb (REGN-EB3), developed by Regeneron, is a three-antibody cocktail designed to target the Ebola virus glycoprotein. The drug was first approved for clinical use in October 2020, but its exact mechanism of action has remained unclear.
A new study led by scientists at La Jolla Institute for Immunology (LJI) shows how ideal antibodies against SARS-CoV-2 hit their marks. Now scientists are looking at how we might harness their power in new antibody therapeutics and even more effective COVID-19 vaccines.
LA JOLLA, CA — Researchers at La Jolla Institute for Immunology (LJI) have at last uncovered how an enzyme called O-GlcNAc transferase (OGT) keeps cells healthy. Their findings, published in the Proceedings of the National Academies of Sciences, reveals a key aspect of cellular biology and may lead to important medical advances.
LJI Instructor Annie Elong Ngono, Ph.D., has spearheaded important studies into the immune response to deadly pathogens such as dengue virus. Now, this dedication to global health and virology has earned her acceptance to the Global Virus Network's (GVN) highly selective Rising Star Mentorship Program.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
